446 related articles for article (PubMed ID: 11252545)
1. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
Hillegass WB; Newman AR; Raco DL
Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
[TBL] [Abstract][Full Text] [Related]
2. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
Plosker GL; Ibbotson T
Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
[TBL] [Abstract][Full Text] [Related]
3. Economic issues in glycoprotein IIb/IIIa receptor therapy.
Hillegass WB; Newman AR; Raco DL
Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
[TBL] [Abstract][Full Text] [Related]
4. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis.
Glaser R; Glick HA; Herrmann HC; Kimmel SE
J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
7. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
Mahoney EM; Jurkovitz CT; Chu H; Becker ER; Culler S; Kosinski AS; Robertson DH; Alexander C; Nag S; Cook JR; Demopoulos LA; DiBattiste PM; Cannon CP; Weintraub WS;
JAMA; 2002 Oct; 288(15):1851-8. PubMed ID: 12377083
[TBL] [Abstract][Full Text] [Related]
8. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
Zeymer U
Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
[TBL] [Abstract][Full Text] [Related]
9. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
10. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes.
Bosanquet N; Jönsson B; Fox KA
Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436
[TBL] [Abstract][Full Text] [Related]
11. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.
Crouch MA; Nappi JM; Cheang KI
Ann Pharmacother; 2003 Jun; 37(6):860-75. PubMed ID: 12773077
[TBL] [Abstract][Full Text] [Related]
13. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Ronner E; Boersma E; Laarman GJ; Somsen GA; Harrington RA; Deckers JW; Topol EJ; Califf RM; Simoons ML
J Am Coll Cardiol; 2002 Jun; 39(12):1924-9. PubMed ID: 12084589
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
Huston SA; Hawkins D
Curr Pharm Des; 2008; 14(12):1197-204. PubMed ID: 18473867
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on eptifibatide in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Curran MP; Keating GM
BioDrugs; 2006; 20(1):63-5. PubMed ID: 16573353
[TBL] [Abstract][Full Text] [Related]
16. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
17. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
Bosch X; Marrugat J
Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
Schriger DL; Herbert ME
Ann Emerg Med; 2001 Sep; 38(3):249-55. PubMed ID: 11524643
[TBL] [Abstract][Full Text] [Related]
19. Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction.
Cannon CP
Clin Cardiol; 1999 Aug; 22(8 Suppl):IV30-6. PubMed ID: 10492851
[TBL] [Abstract][Full Text] [Related]
20. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
McCollam PL; Foster DA; Riesmeyer JS
Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
